Literature DB >> 8103355

Clinical significance of genetic influences on cardiovascular drug metabolism.

L Arcavi1, N L Benowitz.   

Abstract

Inherited differences in metabolism may be responsible for individual variability in the efficacy of drugs and the occurrence of adverse drug reactions. Among the cardiovascular drugs reported to exhibit genetic polymorphism are debrisoquine, sparteine, some beta-adrenoceptor antagonists, flecainide, encainide, propafenone, nifedipine, procainamide, and hydralazine. The implications of genetic differences in the metabolism of these drugs for cardiovascular therapeutics is the subject of this review.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8103355     DOI： 10.1007/bf00880154

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


  86 in total

1.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

Authors:  H H Zhou; R P Koshakji; D J Silberstein; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

2.  High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.

Authors:  G Alvan; C von Bahr; P Seidemann; F Sjöqvist
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

3.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

4.  Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial.

Authors:  T Walle; R P Byington; C D Furberg; K M McIntyre; P S Vokonas
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

5.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors:  E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

6.  Drug interaction between propafenone and metoprolol.

Authors:  F Wagner; D Kalusche; D Trenk; E Jähnchen; H Roskamm
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

7.  Polymorphic hydroxylation of perhexiline maleate in man.

Authors:  R G Cooper; D A Evans; E J Whibley
Journal:  J Med Genet       Date:  1984-02       Impact factor: 6.318

8.  Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.

Authors:  I Strandberg; G Boman; L Hassler; F Sjöqvist
Journal:  Acta Med Scand       Date:  1976

9.  Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.

Authors:  D M Roden; S B Reele; S B Higgins; R F Mayol; R E Gammans; J A Oates; R L Woosley
Journal:  N Engl J Med       Date:  1980-04-17       Impact factor: 91.245

10.  The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.

Authors:  G Mikus; A S Gross; J Beckmann; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875
View more
  2 in total

Review 1.  Selecting the right drug for initial antihypertensive therapy.

Authors:  A B Weder
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 2.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.